IDEAYA Biosciences Q3 loss widens to $125.7 million
Key points
- IDEAYA Biosciences reported a third-quarter 2026 net loss of $125.7 million, widening from $112.5 million in the previous quarter.
- Collaboration revenue rose to $10.2 million, while cash and marketable securities declined to approximately $1.15 billion from $1.24 billion.
- IDEAYA completed its first darovasertib FDA application and expects $100 million–$125 million in savings from closing a Phase 3 trial.
IDEAYA Biosciences (NASDAQ:IDYA) reported a third-quarter 2026 net loss of $125.7 million while completing its first FDA application for darovasertib.
The loss widened from $112.5 million in the second quarter, although collaboration revenue increased to $10.2 million from $8.9 million.
Cash and marketable securities declined to $1.15 billion from $1.24 billion, while IDEAYA expects $100 million–$125 million in savings from closing OptimUM-010.
IDEAYA maintained its cash runway guidance into 2030 and submitted darovasertib plus crizotinib for potential FDA approval in metastatic uveal melanoma.
The company initiated the separate Phase 3 OptimUM-011 trial with Servier, targeting approximately 450 patients with high-risk primary uveal melanoma.
IDEAYA also plans two Phase 3 IDE849 trials by year-end, with initial global Phase 1/2 data expected by late 2026 or early 2027.
Frequently asked questions
More from United States
Dynatrace Q2 revenue increases 17% to $580 million
Thomson Reuters records double-digit Q3 revenue growth
Icahn Enterprises unveils $225 million Q3 loss
Keurig Dr Pepper delivers $7.34 billion Q3 sales as earnings beat estimates
Shopify posts double-digit Q3 sales growth as revenue hits $3.74B
Apollo Q3 net loss reaches $1.06bn
